# Phase 2 dermatitis trials recruiting: 32 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 32 trials in phase 2 for dermatitis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 dermatitis trials: 32 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/dermatitis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 32
- Recruiting or not yet: 32
- Read on: November 19, 2026

## Trials

The 25 newest of 32, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 3, 2026 | NCT07914088 | A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis | Arjil Pharmaceuticals LLC | Phase 2 | Recruiting | Dermatitis Atopic | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914088) |
| October 26, 2026 | NCT07895615 | Phase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With Moderate-to-Severe Atopic... | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | Phase 2 | Recruiting | Atopic Dermatitis (AD) | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895615) |
| September 28, 2026 | NCT07843290 | A Study of JYP0066 Cream in Mild-to-Moderate Atopic Dermatitis | Guangzhou JOYO Pharma Co., Ltd | Phase 2 | Not yet recruiting | Atopic Dermatitis (AD) | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843290) |
| September 9, 2026 | NCT07810777 | PRA-216 Atopic Dermatitis Safety and Efficacy Study | Prana Therapies Inc | Phase 2 | Recruiting | Atopic Dermatitis (AD) | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07810777) |
| August 24, 2026 | NCT07782333 | A Study Evaluating TRIV-573 in Atopic Dermatitis | Sponsor not shown (see the record) | Phase 2 | Recruiting | Atopic Dermatitis | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07782333) |
| July 1, 2026 | NCT07678645 | The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching | RenJi Hospital | Phase 2 | Not yet recruiting | Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Atopic Dermatitis (AD) | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07678645) |
| June 12, 2026 | NCT07643766 | A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis | Enveda Therapeutics | Phase 2 | Recruiting | Atopic Dermatitis | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07643766) |
| June 2, 2026 | NCT07620561 | Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients | University of Maryland, Baltimore | Phase 2 | Not yet recruiting | Prurigo Nodularis (PN) | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07620561) |
| May 20, 2026 | NCT07599813 | A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis | Apollo Therapeutics Ltd | Phase 2 | Recruiting | Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis... | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07599813) |
| May 20, 2026 | NCT07598383 | A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in... | Jiangsu vcare pharmaceutical technology co., LTD | Phase 2 | Recruiting | Atopic Dermatitis | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07598383) |
| March 3, 2026 | NCT07445919 | A Clinical Study to Evaluate SM17 for Atopic Dermatitis | SinoMab BioScience Ltd | Phase 2 | Recruiting | Atopic Dermatitis | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07445919) |
| March 2, 2026 | NCT07441395 | Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD | Corvus Pharmaceuticals, Inc. | Phase 2 | Recruiting | Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema, Eczema, Atopic | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07441395) |
| February 10, 2026 | NCT07399067 | A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 | Recruiting | Atopic Dermatitis | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07399067) |
| December 23, 2025 | NCT07298395 | Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis | Enveda Therapeutics | Phase 2 | Recruiting | Atopic Dermatitis (AD) | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07298395) |
| December 22, 2025 | NCT07297602 | Evaluation of Efficacy and Safety of Oral Roflumilast for Treatment of Moderate to Severe Atopic Dermatitis in Patients Aged 12 Years and... | Sponsor not shown (see the record) | Phase 2 | Recruiting | Atopic Dermatitis | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07297602) |
| November 21, 2025 | NCT07242638 | Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome | Icahn School of Medicine at Mount Sinai | Phase 2 | Recruiting | Atopic Dermatitis, Alopecia Areata | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07242638) |
| November 17, 2025 | NCT07230483 | A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis. | Keymed Biosciences Co.Ltd | Phase 2 | Recruiting | Atopic Dermatitis (AD) | 246 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07230483) |
| October 14, 2025 | NCT07216027 | A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema | Pfizer | Phase 2 | Recruiting | Atopic Dermatitis, Eczema, Atopic | 165 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07216027) |
| September 26, 2025 | NCT07193589 | A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 2 | Recruiting | Atopic Dermatitis | 111 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07193589) |
| July 8, 2025 | NCT07054736 | Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic Dermatitis | Zhejiang Kanova Biopharmaceutical Co., LTD | Phase 2 | Not yet recruiting | Atopic Dermatitis | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07054736) |
| June 26, 2025 | NCT07037901 | A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis | Inmagene LLC | Phase 2 | Recruiting | Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema | 405 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037901) |
| June 4, 2025 | NCT07003425 | A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis | Apogee Therapeutics, Inc. | Phase 2 | Recruiting | Atopic Dermatitis | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07003425) |
| April 27, 2025 | NCT06947993 | Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis | Novartis Pharmaceuticals | Phase 2 | Recruiting | Atopic Dermatitis | 224 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06947993) |
| April 27, 2025 | NCT06947980 | Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis | Keymed Biosciences Co.Ltd | Phase 2 | Recruiting | Atopic Dermatitis | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06947980) |
| March 4, 2025 | NCT06855745 | Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD. | Sponsor not shown (see the record) | Phase 2 | Recruiting | Atopic Dermatitis (Eczema), Atopic Dermatitis Eczema, Atopic Dermatitis, Atopic Dermatitis (AD), Eczema, Eczema, Atopic | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06855745) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| Enveda Therapeutics | 2 |
| [Keymed Biosciences Co.Ltd](https://specstream.ai/data/clinical-trials/company/keymed-biosciences-co-ltd) | 2 |
| Apollo Therapeutics Ltd | 1 |
| Icahn School of Medicine at Mount Sinai | 1 |
| [Chengdu Zenitar Biomedical Technology Co., Ltd](https://specstream.ai/data/clinical-trials/company/chengdu-zenitar-biomedical-technology-co-ltd) | 1 |
| Corvus Pharmaceuticals, Inc. | 1 |
| Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | 1 |
| Apogee Therapeutics, Inc. | 1 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 1 |
| Inmagene LLC | 1 |
| University of Maryland, Baltimore | 1 |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 1 |
| [Jiangsu vcare pharmaceutical technology co., LTD](https://specstream.ai/data/clinical-trials/company/jiangsu-vcare-pharmaceutical-technology-co-ltd) | 1 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 1 |
| SinoMab BioScience Ltd | 1 |
| [Innovent Biologics (Suzhou) Co. Ltd.](https://specstream.ai/data/clinical-trials/company/innovent-biologics-suzhou-co-ltd) | 1 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 1 |
| [Oneness Biotech Co., Ltd.](https://specstream.ai/data/clinical-trials/company/oneness-biotech-co-ltd) | 1 |
| Zhejiang Kanova Biopharmaceutical Co., LTD | 1 |
| Guangzhou JOYO Pharma Co., Ltd | 1 |
| Prana Therapies Inc | 1 |
| Enzychem Lifesciences Corporation | 1 |
| RenJi Hospital | 1 |
| [Akeso](https://specstream.ai/data/clinical-trials/company/akeso) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 16 |
| China | 12 |
| Canada | 6 |
| Czechia | 4 |
| Germany | 4 |
| Poland | 4 |
| Hungary | 3 |
| Spain | 3 |
| France | 3 |
| Australia | 3 |
| Taiwan | 3 |
| Bulgaria | 2 |
| United Kingdom | 2 |
| New Zealand | 2 |
| Japan | 2 |
| Ukraine | 1 |
| Egypt | 1 |
| Argentina | 1 |
| Italy | 1 |
| Netherlands | 1 |
| Slovakia | 1 |
| South Korea | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Spanish restaurants in the United States](https://specstream.ai/data/businesses/spanish-restaurants/united-states)
- [Carpet cleaning companies in the United States](https://specstream.ai/data/businesses/carpet-cleaning-companies/united-states)
- [IT companies in the United States](https://specstream.ai/data/businesses/it-companies/united-states)
- [Steel fabricators in the United States](https://specstream.ai/data/businesses/steel-fabricators/united-states)
- [Children's hospitals in the United States](https://specstream.ai/data/businesses/childrens-hospitals/united-states)
- [Kosher restaurants in the United States](https://specstream.ai/data/businesses/kosher-restaurants/united-states)
